Collectively, these results reinforce the notion that inhibiting XOR with febuxostat exerts a potential therapeutic effect on high-fat diet-induced MASLD by ameliorating lipid dysregulation in rat models. This evidence concerns the gene XDH and metabolic dysfunction-associated steatotic liver disease.